{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:37:13Z","timestamp":1794465433766,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA015083"],"award-info":[{"award-number":["P30 CA015083"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA015083"],"award-info":[{"award-number":["P30 CA015083"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA210964"],"award-info":[{"award-number":["P50 CA210964"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA210964"],"award-info":[{"award-number":["P50 CA210964"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UM1 CA186686"],"award-info":[{"award-number":["UM1 CA186686"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UM1 CA186686"],"award-info":[{"award-number":["UM1 CA186686"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UM1 CA186686"],"award-info":[{"award-number":["UM1 CA186686"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UM1 CA186686"],"award-info":[{"award-number":["UM1 CA186686"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s10637-024-01420-8","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T05:02:17Z","timestamp":1706158937000},"page":"127-135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort"],"prefix":"10.1007","volume":"42","author":[{"given":"Oluwadunni E.","family":"Emiloju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Koubek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh J.","family":"Borad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Seetharam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Edelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Sausville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed O.","family":"Kaseb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Posey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Gores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis R.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Takebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary K.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea E. Wahner","family":"Hendrickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott H.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex A.","family":"Adjei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joleen M.","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"issue":"9","key":"1420_CR1","doi-asserted-by":"publisher","first-page":"-","DOI":"10.15252\/embr.201745235","volume":"19","author":"J Kale","year":"2018","unstructured":"Kale J et al (2018) Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance. EMBO Rep 19(9)","journal-title":"EMBO Rep"},{"issue":"9","key":"1420_CR2","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C et al (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68(9):3421\u20133428","journal-title":"Cancer Res"},{"issue":"15","key":"1420_CR3","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1200\/JCO.21.02188","volume":"40","author":"CN Harrison","year":"2022","unstructured":"Harrison CN et al (2022) Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. J Clin Oncol 40(15):1671\u20131680","journal-title":"J Clin Oncol"},{"issue":"6","key":"1420_CR4","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA et al (2021) Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov 11(6):1440\u20131453","journal-title":"Cancer Discov"},{"issue":"11","key":"1420_CR5","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","volume":"18","author":"CM Rudin","year":"2012","unstructured":"Rudin CM et al (2012) Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 18(11):3163\u20133169","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1420_CR6","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1158\/1078-0432.CCR-20-4084","volume":"27","author":"EM Bertino","year":"2021","unstructured":"Bertino EM et al (2021) Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clin Cancer Res 27(6):1604\u20131611","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1420_CR7","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1200\/JCO.2011.37.9339","volume":"30","author":"LD Walensky","year":"2012","unstructured":"Walensky LD (2012) From mitochondrial biology to magic bullet: navitoclax disarms BCL-2 in chronic lymphocytic leukemia. J Clin Oncol 30(5):554\u2013557","journal-title":"J Clin Oncol"},{"issue":"1","key":"1420_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ygyno.2022.01.021","volume":"165","author":"F Joly","year":"2022","unstructured":"Joly F et al (2022) A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study. Gynecol Oncol 165(1):30\u201339","journal-title":"Gynecol Oncol"},{"issue":"21","key":"1420_CR9","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-18-0549","volume":"24","author":"S Arai","year":"2018","unstructured":"Arai S et al (2018) Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL\/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. Clin Cancer Res 24(21):5458\u20135470","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1420_CR10","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1002\/hep.23836","volume":"52","author":"H Hikita","year":"2010","unstructured":"Hikita H et al (2010) The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology 52(4):1310\u20131321","journal-title":"Hepatology"},{"issue":"24","key":"1420_CR11","doi-asserted-by":"publisher","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","volume":"66","author":"L Liu","year":"2006","unstructured":"Liu L et al (2006) Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5. Cancer Res 66(24):11851\u201311858","journal-title":"Cancer Res"},{"issue":"3","key":"1420_CR12","first-page":"515","volume":"21","author":"J Watanabe","year":"2002","unstructured":"Watanabe J et al (2002) Bcl-xL overexpression in human hepatocellular carcinoma. Int J Oncol 21(3):515\u2013519","journal-title":"Int J Oncol"},{"issue":"41","key":"1420_CR13","doi-asserted-by":"publisher","first-page":"29831","DOI":"10.1074\/jbc.M706110200","volume":"282","author":"XW Meng","year":"2007","unstructured":"Meng XW et al (2007) Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43\u20139006)-induced TRAIL sensitization. J Biol Chem 282(41):29831\u201329846","journal-title":"J Biol Chem"},{"issue":"8","key":"1420_CR14","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/s41419-021-04020-z","volume":"12","author":"S Busche","year":"2021","unstructured":"Busche S et al (2021) BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment. Cell Death Dis 12(8):736","journal-title":"Cell Death Dis"},{"issue":"4","key":"1420_CR15","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/sj.leu.2405098","volume":"22","author":"W Zhang","year":"2008","unstructured":"Zhang W et al (2008) Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 22(4):808\u2013818","journal-title":"Leukemia"},{"issue":"3","key":"1420_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"1420_CR17","doi-asserted-by":"publisher","first-page":"-","DOI":"10.3390\/cancers11060873","volume":"11","author":"PM Gholam","year":"2019","unstructured":"Gholam PM, Iyer R, Johnson MS (2019) Multidisciplinary Management of Patients with Unresectable Hepatocellular Carcinoma: A Critical Appraisal of Current Evidence. Cancers (Basel) 11(6)","journal-title":"Cancers (Basel)"},{"issue":"4","key":"1420_CR18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378\u2013390","journal-title":"N Engl J Med"},{"issue":"1","key":"1420_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1191\/1740774506cn134oa","volume":"3","author":"E Garrett-Mayer","year":"2006","unstructured":"Garrett-Mayer E (2006) The continual reassessment method for dose-finding studies: a tutorial. Clin Trials 3(1):57\u201371","journal-title":"Clin Trials"},{"issue":"11","key":"1420_CR20","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/sim.4780141102","volume":"14","author":"SN Goodman","year":"1995","unstructured":"Goodman SN, Zahurak ML, Piantadosi S (1995) Some practical improvements in the continual reassessment method for phase I studies. Stat Med 14(11):1149\u20131161","journal-title":"Stat Med"},{"key":"1420_CR21","unstructured":"National Institutes of Health, National Cancer Institute (2009) Common Terminology criteria for adverse events (CTCAE) version 4.0, D.o.H.a.H. Services, Editor"},{"issue":"2","key":"1420_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u201347","journal-title":"Eur J Cancer"},{"key":"1420_CR23","unstructured":"Sorafenib (2018) [Package insert] Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021923s020lbl.pdf"},{"key":"1420_CR24","doi-asserted-by":"publisher","first-page":"6861","DOI":"10.1038\/sj.onc.1208841","volume":"24","author":"C Yu","year":"2005","unstructured":"Yu C et al (2005) The Role of Mcl-1 Down-regulation in the Pro-apoptotic Activity of the Raf Kinase Inhibitor BAY 43\u20139006. Oncogene 24:6861\u20136869","journal-title":"Oncogene"},{"issue":"10064","key":"1420_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389(10064):56\u201366","journal-title":"Lancet"},{"issue":"10126","key":"1420_CR26","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163\u20131173","journal-title":"Lancet"},{"issue":"1","key":"1420_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK et al (2018) Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 379(1):54\u201363","journal-title":"N Engl J Med"},{"issue":"2","key":"1420_CR28","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX et al (2019) Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(2):282\u2013296","journal-title":"Lancet Oncol"},{"issue":"20","key":"1420_CR29","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS et al (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382(20):1894\u20131905","journal-title":"N Engl J Med"},{"issue":"2","key":"1420_CR30","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL et al (2022) Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 76(2):862\u2013873","journal-title":"J Hepatol"},{"issue":"8","key":"1420_CR31","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK et al (2022) Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evidence 1(8):EVIDoa2100070","journal-title":"NEJM Evidence"},{"issue":"11","key":"1420_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4564","volume":"6","author":"T Yau","year":"2020","unstructured":"Yau T et al (2020) Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol 6(11):e204564","journal-title":"JAMA Oncol"},{"issue":"5","key":"1420_CR33","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00280-015-2882-9","volume":"76","author":"AW Tolcher","year":"2015","unstructured":"Tolcher AW et al (2015) Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study. Cancer Chemother Pharmacol 76(5):1041\u20131049","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"1420_CR34","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s10637-014-0110-9","volume":"32","author":"JM Cleary","year":"2014","unstructured":"Cleary JM et al (2014) A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Invest New Drugs 32(5):937\u2013945","journal-title":"Invest New Drugs"},{"issue":"21","key":"1420_CR35","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.2217\/fon-2021-0140","volume":"17","author":"M Puglisi","year":"2021","unstructured":"Puglisi M et al (2021) A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors. Future Oncol 17(21):2747\u20132758","journal-title":"Future Oncol"},{"issue":"5","key":"1420_CR36","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s10637-014-0116-3","volume":"32","author":"G Vlahovic","year":"2014","unstructured":"Vlahovic G et al (2014) A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin\/paclitaxel in the treatment of patients with solid tumors. Invest New Drugs 32(5):976\u2013984","journal-title":"Invest New Drugs"},{"issue":"5","key":"1420_CR37","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00280-015-2883-8","volume":"76","author":"AW Tolcher","year":"2015","unstructured":"Tolcher AW et al (2015) Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors. Cancer Chemother Pharmacol 76(5):1025\u20131032","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01420-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01420-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01420-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T10:08:06Z","timestamp":1708682886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01420-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1420"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01420-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]},"assertion":[{"value":"31 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J. R.- Consulting or Advisory Role for Elucida Oncology. Y.L.- Consulting or Advisory Role for AstraZeneca, Janssen, Lilly, Turning Point Therapeutics; Research Funding to Institution from Merck, Tolero Pharmaceuticals, Blueprint Medicines, Daiichi Sankyo, Genmab, Mirati Therapeutics, Roche\/Genentech. M.S.- Honoraria from Horizon CME, Daiichi Sankyo, Deciphera, AADi; Travel, Accommodations, Expenses from Horizon CME. M.E.-Consulting or Advisory Role for WindMIL, Flame Biosciences, Sanofi\/Regeneron, Kanaph Therapeutics, Coherus BioSciences, GE Healthcare, BioAtla; Travel, Accommodations, Expenses from Nektar; Research Funding to institution from Bristol-Myers Squibb, Apexigen, Nektar, GlaxoSmithKline, Windmil, United Therapeutics; Patent application for radiopharmaceutical to treat small cell lung cancer by Institution; Stock and Other Ownership Interests in Biomarker Strategies, Creatv MicroTech; Other Relationship: AstraZeneca\/MedImmune, Boehringer Ingelheim, Takeda, Seagen, Anheart Therapeutics. A.K.- Consulting or Advisory Role for Bayer Health, Bristol-Myers Squibb, Merck, Exelixis, Genentech\/Roche, Eisai, AstraZeneca; Research Funding to institution from Bristol-Myers Squibb, Merck, Bayer\/Onyx, Genentech, Adaptimmune, Hengrui Pharmaceutical; Honoraria from Merck, Exelixis, Bayer Health, Bristol-Myers Squibb, Eisai, Genentech\/Roche, AstraZeneca; Travel, Accommodations, Expenses from Exelixis, Merck, Bayer\/Onyx, Bristol-Myers Squibb, Eisai, Genentech\/Roche, AstraZeneca. J.P.- Consulting or Advisory Role for Lilly, Seagen. S.D.- Research Funding to institution from Bristol-Myers Squibb, Merck, Boston Scientific, Symphogen, I-Mab, TriSalus Life Sciences, Tvardi Therapeutics, EMD Serono, ORIC Pharmaceuticals; Stock and Other Ownership Interests in Johnson & Johnson\/MedTech. L.R- has received grant support from ARIAD Pharmaceuticals, Bayer, BTG International, Exact Sciences, Gilead Sciences, Glycotest, RedHill, Target PharmaSolutions, and Wako Diagnostics; he has provided advisory services to Bayer, Exact Sciences, Gilead Sciences, GRAIL, QED Therapeutics, and TAVEC. G.S.- Consulting or Advisory Role to Bionaut Labs, Ellipses Pharma, Gencirq, Epizyme, Array BioPharma, Apexigen, Oncogenuity, Oncusp Therapeutics, Concarlo, Shanghai Pharma, Astex Pharmaceuticals, January Therapeutics, Sellas Life Sciences, PureTech, AADi, Kirilys Therapeutics, Agenus, Boehringer Ingelheim, Ipsen; Travel, Accommodations, Expenses from Array BioPharma, Epizyme, Boehringer Ingelheim; Patents, Royalties, Other Intellectual Property by institution Companion diagnostics for CD4 inhibitors, Patent granted to develop a new technology called PNAs for cancer therapy; Stock and Other Ownership Interests in GenCirq, Bionaut Labs, January Therapeutics; Research Funding to institution from Astex Pharmaceuticals, Incyte, Calithera Biosciences, Lilly, Daiichi Sankyo, Fortress Biotech, Karyopharm Therapeutics, Oxford BioTherapeutics, Astex Pharmaceuticals, TopAlliance BioSciences Inc, Adaptimmune, SpringWorks Therapeutics, TRACON Pharma. A.WH.- Research Funding to institution from ProLynx, Amgen; Patents, Royalties, Other Intellectual Property by institution in TORL Therapeutics; Consulting or Advisory Role for Oxcia; Speakers' Bureau for OncLive. S.K.- Consulting or Advisory Role for Attivare Therapeutics; Research Funding to Institution from Takeda; Patents, Royalties, Other Intellectual Property owned by Mayo Clinic an antibody developed in the Kaufmann laboratory; Uncompensated Relationships with ProLynx. A.A.- Consulting or Advisory Role for Janssen, EMD Serono, Zai Lab, Swiss Rockets, Mirati Therapeutics; Research Funding to institution from Bayer Schering Pharma, Tesaro, I-Mab, Kura Oncology, Merck KGaA, Zai Lab, Jacobio; Uncompensated Relationships with Merck KGaA, Zai Lab, Swiss Rockets. J.H.- reports advisory funds from Bayer, Merck, BeiGene, Incyte, Taiho; and research funding to institution from Merck, Treos Bio, Senhwa pharmaceuticals, Bayer, Incyte, TriOncology, Seattle Genetics, Hutchison MediPharma, Pionyr Immunotherapeutics, Trovogene, G1 Therapeutics, Roche, Pfizer, Cardiff Oncology, Mirati Therapeutics, Xilis Inc. B.C.- Research Funding to institution from GlaxoSmithKline\/Novartis; Speakers' Bureau for Clinical Care Options\/NCCN.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}